NanoPalm pioneers biorobot therapy for sickle cell disease

Sickle cell disease, a genetic blood disorder affecting millions worldwide, is the target of a groundbreaking biorobot development by Saudi-based NanoPalm. This innovative approach combines artificial intelligence, nanotechnology, and gene therapy to revolutionize treatment for this debilitating condition.

Founded in 2022 in Riyadh, NanoPalm emerged from the prestigious King Abdulaziz City for Science and Technology (KACST) and received crucial support from the NextEra initiative. Led by experts Ali Al-Hasan and Samar Al-Sudir, the company is at the forefront of nanomedicine and chemistry, aiming to eliminate the gene responsible for sickle cell disease.

NanoPalm's cutting-edge strategy involves leveraging AI to predict optimal gene therapies, utilizing nanotechnology to create specialized medicine, and employing gene therapy to edit genetic material. By harnessing data-driven AI models, the team streamlines treatment processes, ensuring efficacy and affordability for patients.

The core of NanoPalm's solution lies in lipid biorobots that encapsulate genetic materials acting as 'scissors' to target and remove the disease-causing gene within patients. Administered through IV infusion, these biorobots navigate the body, specifically targeting cells associated with sickle cell disease during clinic visits.

With a mission to transform the biotech landscape, NanoPalm not only aims to combat sickle cell disease but also intends to tackle numerous genetic disorders lacking effective treatments. Through strategic partnerships, the company plans to introduce its groundbreaking product in 2030, potentially benefiting thousands of individuals in Saudi Arabia and beyond.

NanoPalm's pioneering efforts in utilizing AI, nanotechnology, and gene therapy to combat sickle cell disease signify a significant advancement in biotechnology. Their commitment to affordability and accessibility holds promise for revolutionizing treatment options for genetic diseases, offering hope to patients worldwide.